Ethionamide Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 250 mg
Reference Brands: Generic formulations marketed under different names
Category:
Respiratory Disorder
Ethionamide is available in Tablets
and strengths such as 250 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ethionamide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ethionamide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ethionamide, also known as ETA or ETH, is an oral antibiotic used primarily in the treatment of tuberculosis, particularly multidrug-resistant tuberculosis (MDR-TB). It is used in combination with other antituberculosis medications as part of a second-line regimen to ensure effective bacterial eradication and prevent the development of further drug resistance.
Ethionamide exhibits antimicrobial activity against Mycobacterium tuberculosis, M. bovis, and M. smegmatis, and is occasionally used against M. leprae and other nontuberculous mycobacteria, including M. avium and M. kansasii. It works by inhibiting mycolic acid synthesis in the bacterial cell wall, preventing bacterial growth and replication. While its mechanism is similar to isoniazid, cross-resistance occurs in only a small percentage of strains because both drugs are prodrugs activated by different pathways.
Ethionamide is administered orally under medical supervision, usually as part of a combination therapy. Regular monitoring is recommended to assess treatment efficacy and detect potential side effects, including gastrointestinal disturbances and hepatotoxicity. Its targeted activity against resistant mycobacterial strains makes ethionamide a valuable option in the management of complex tuberculosis infections.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing